Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

Bone Therapeutics Secures EUR 5 Million Financing

  • Read more about Bone Therapeutics Secures EUR 5 Million Financing

Bone Therapeutics announces 2021 full year results

  • Read more about Bone Therapeutics announces 2021 full year results

Bone Therapeutics to host Annual General Meeting and Extraordinary General Meeting on 8 June 2022

  • Read more about Bone Therapeutics to host Annual General Meeting and Extraordinary General Meeting on 8 June 2022

Bone Therapeutics enters into exclusive reverse merger discussions with Medsenic

  • Read more about Bone Therapeutics enters into exclusive reverse merger discussions with Medsenic

Bone Therapeutics signs definitive subscription agreement for a maximum of EUR 5M convertible bonds facility with ABO

  • Read more about Bone Therapeutics signs definitive subscription agreement for a maximum of EUR 5M convertible bonds facility with ABO

Bone Therapeutics Provides First Quarter 2022 Business Update

  • Read more about Bone Therapeutics Provides First Quarter 2022 Business Update

Bone Therapeutics to host Extraordinary General Meeting on 13 July 2022

  • Read more about Bone Therapeutics to host Extraordinary General Meeting on 13 July 2022

Bone Therapeutics: Information on the total number of voting rights and shares

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares

Bone Therapeutics optimizes statistical analysis and introduces interim analysis in the ongoing ALLOB Phase IIb study for high-risk tibial fractures

  • Read more about Bone Therapeutics optimizes statistical analysis and introduces interim analysis in the ongoing ALLOB Phase IIb study for high-risk tibial fractures

Bone Therapeutics: Information on the total number of voting rights and shares

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions